Detalhe da pesquisa
1.
Genomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALL.
Blood
; 2024 Mar 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-38551807
2.
Interrogating bromodomain inhibitor resistance in KMT2A-rearranged leukemia through combinatorial CRISPR screens.
Proc Natl Acad Sci U S A
; 120(16): e2220134120, 2023 04 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-37036970
3.
Erythroid/megakaryocytic differentiation confers BCL-XL dependency and venetoclax resistance in acute myeloid leukemia.
Blood
; 141(13): 1610-1625, 2023 03 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-36508699
4.
Venetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trial.
Blood
; 141(11): 1265-1276, 2023 03 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-36265087
5.
North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need.
Blood
; 141(6): 567-578, 2023 02 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-36399715
6.
Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody-drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1/2 study.
Lancet Oncol
; 25(3): 388-399, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38423051
7.
Tagraxofusp, a first-in-class CD123-targeted agent: Five-year postapproval comprehensive review of the literature.
Cancer
; 2024 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38620053
8.
Evidence supporting a role for the immune checkpoint protein B7-H3 in NK cell-mediated cytotoxicity against AML.
Blood
; 139(18): 2782-2796, 2022 05 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35231101
9.
Acute myeloid leukemia with mast cell differentiation is characterized by interstitial mast cells, complex karyotype, TP53 alterations and poor prognosis.
Haematologica
; 2024 Mar 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-38546693
10.
Molecular responses in decitabine- and decitabine/venetoclax-treated patients with acute myeloid leukemia and myelodysplastic syndromes.
Haematologica
; 2024 Apr 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-38618679
11.
Diagnosing and Treating Blastic Plasmacytoid Dendritic Cell Neoplasm in a Resource-Limited Setting.
Oncology (Williston Park)
; 38(3): 104-106, 2024 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38517410
12.
Novel Therapeutic Targets in Acute Myeloid Leukemia (AML).
Curr Oncol Rep
; 26(4): 409-420, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38502417
13.
Author Correction: Metabolic gatekeeper function of B-lymphoid transcription factors.
Nature
; 558(7711): E5, 2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29849140
14.
Triple combination targeting methyltransferase, BCL-2, and PD-1 facilitates antileukemia responses in acute myeloid leukemia.
Cancer
; 129(4): 531-540, 2023 02 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-36477735
15.
A retrospective study of cladribine and low-dose cytarabine-based regimens for the treatment of chronic myelomonocytic leukemia and secondary acute myeloid leukemia.
Cancer
; 129(4): 560-568, 2023 02 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-36458426
16.
Early mortality in acute myeloid leukemia with KMT2A rearrangement is associated with high risk of bleeding and disseminated intravascular coagulation.
Cancer
; 129(12): 1856-1865, 2023 06 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-36892949
17.
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia.
N Engl J Med
; 383(7): 617-629, 2020 08 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-32786187
18.
DYRK1a mediates BAFF-induced noncanonical NF-κB activation to promote autoimmunity and B-cell leukemogenesis.
Blood
; 138(23): 2360-2371, 2021 12 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34255829
19.
Venetoclax enhances T cell-mediated antileukemic activity by increasing ROS production.
Blood
; 138(3): 234-245, 2021 07 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-34292323
20.
Clonal dynamics and clinical implications of postremission clonal hematopoiesis in acute myeloid leukemia.
Blood
; 138(18): 1733-1739, 2021 11 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-34115096